DOCSLIB.ORG

Diagnostica Stago, Inc. Product Catalog 2015 STA® Family of Hemostasis Analyzers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Diagnostica Stago, Inc. Product Catalog 2015 STA® Family of Hemostasis Analyzers Diagnostica Stago, Inc. Product Catalog 2015 STA® Family of Hemostasis Analyzers The STA® Family of MODELS: AUTOMATED STA-R Evolution® Expert Series: Automation capable, high throughput Hemostasis Analyzers STA Compact Max®: Moderate throughput provides automation of STA Satellite®: Low throughput coagulation testing MODELS: SEMI-AUTOMATED for a variety of STart® laboratory situations. FEATURES Each system performs Host-query bi-directional interface clotting, chromogenic Primary tube sampling Continuous sample access and immunoassay Open reagent system methodologies in Reagent and disposable management random access Reagent level detection QC management with Levy-Jennings mode. Because all Reagent and sample bar code reader STA® analyzers use Auto re-run and auto re-dilute options Programmable and pre-programmed options the same analysis methods Up to 70 on-board reagent capacity and the same reagent Capacity of up to 1,000 disposable cuvettes formulations, they offer Multi-constituent controls and calibrator standardization in METHODOLOGIES Clotting - VDS™ Mechanical Clot Detection the laboratory. Chromogenic - Optical density Immunological - Optical density STA® ASSAY MENU PT APTT Fibrinogen (Clauss) D-dimer (Quantitative) Thrombin Time Reptilase Time Extrinsic Factors Intrinsic Factors Anti-Xa Activity Unfractionated Heparin (UFH) Low Molecular Weight Heparin (LMWH) Rivaroxaban* Apixaban* Edoxaban* Ecarin Chromogenic Assay (ECA-II)* Dabigatran* Antithrombin (AT) Activity Antithrombin (AT) Antigen Protein C Activity (clot-based and chromogenic) Protein S Activity Free Protein S Antigen Total Protein S Antigen VWF Antigen Plasminogen Activity Antiplasmin Activity Fibrin Monomer* Lupus Anticoagulants [ PTT-LA Staclot LA *(research use only; not for use in diagnostic procedures) 2 Product Catalog 2015 Section 1 Instruments . 3 Section 2 Disposables & Accessories . 7 Section 3 Screening Tests . 10 Section 4 Factor Assays . .11 Section 5 Anticoagulants . 12 Section 6 Thrombophilia . 12 Section 7 Fibrin Formation & Degradation . 15 Section 8 Fibrinolysis . 16 Section 9 Primary Hemostasis . 16 Section 10 Control Plasmas. .17 Section 11 Calibrators . 18 Section 12 Auxiliary Reagents . 18 Section 13 Quality & Compliance Solutions . 19 Section 14 Stago Added Value on Request (SAVOR™) . 20 Section 15 Thrombin Generation Research Products . 26 Section 16 Ecarin Chromogenic Assay (ECA) Products . 27 Section 17 Flow Cytometry Research Products . 29 Section 18 Research Kits . 31 Section 19 Research Components . 35 Abbreviations . 36 Table of Contents Table Terms & Conditions . 38 Main Index . 39-40 For the most up-to-date information on all our products, contact the Diagnostica Stago, Inc. Marketing Dept. at 800-222-COAG or visit our website at www.stago-us.com. PRODUCT AVAILABILITY: Most clinical reagents are available within 5 days after receipt of order. However if a sequestered lot of reagent is required, please contact Sales Administration for availability. For availability of research products, please contact Sales Administration at 800-222-COAG, option 3. Research products not in stock may require a 60-day notice prior to availability. 1 Instruments (continued) Section 1 CAT. NO. PRODUCT/ DESCRIPTION 58978 STA-R Evolution® Expert Series Hemostasis System Fully Automated, High-Throughput Hemostasis Analyzer (Automation-Capable) 58979 STA-R Evolution® Expert Series Hemostasis System with Cap Piercing Fully Automated, High-Throughput Hemostasis Analyzer (Automation-Capable) The STA-R Evolution® Expert Series is a fully automated, hemostasis analyzer with laboratory automation connection capability. Clotting, chromogenic and immunological assays are performed simultaneously in random access mode. The system’s unique method of sample management offers high throughput and rapid processing of STAT samples without interrupting ongoing testing. Along with Stago’s exclusive method of VDS TM Mechanical Clot Detection (Viscosity-based Detection System) technolo- gy and implementation of Windows-based* software, the STA-R Evolution® Expert Series incorporates features such as QC commenting, enhanced traceability and various export formats. Analyzer is provided with: \ Color printer, printer stand and keyboard Uninterruptible power supply Operator’s reference manual Accessory kit 1-year warranty Dimensions • Height . 49.2 inches • Width . 50.3 inches • Depth . 32.2 inches • Weight . 564 pounds Test Selections !!" Samples • 215 onboard sample capacity • Primary tube sampling • 5 samples per rack • Continuous sample access • True STAT management LIS Interface Bi-directional host-query Automation Compatible with all major automation line solutions Reagent Menu 70 reagent positions capable of performing a complete range of routine and specialty tests. Contact your Stago Representative for the most current listing. STA-R Evolution® *Windows is a trademark of Microsoft Corporation. 3 Section 1 Instruments (continued) CAT. NO. PRODUCT/ DESCRIPTION 58990 STA Compact Max® Coagulation System Fully Automated, Moderate-Throughput Hemostasis Analyzer 58989 STA Compact Max® Coagulation System Cap Piercing Model Fully Automated, Moderate-Throughput Hemostasis Analyzer The STA Compact Max® is a fully automated, benchtop hemostasis workstation capable of performing clotting, chromogenic and immunological assays simultaneously in random access mode. The system’s unique method of sample management offers moderate throughput and rapid processing of STAT samples without the need to interrupt current testing. All sample and calibrator dilutions are performed automatically, increasing staff productivity for laboratories performing moderate-volume routine and specialty coagulation testing. The STA Compact Max® takes innovation to the next level by adding state of the art data automation with the Expert Module software. The combination of VDS methodology and the Expert Module on the STA Compact Max®#$%&%%'+ Analyzer is provided with: • Expert Module Computer and Software • 22 inch color touch screen • Laser printer • Uninterruptible power supply • Operator’s reference manual • Accessory kit • 1-year warranty Dimensions • Height . 27.75 inches • Width . 38.18 inches • Depth . 28.73 inches • Weight . 309 pounds Test Selections /!" Samples • 96 primary sample tubes onboard: - 84 positions for primary tubes - 12 positions for pediatric tubes • Continous sample access • True STAT Management without impact on throughput #=$" LIS Interface Bi-directional host-query or dynamic download Reagent Menu 45 reagent positions capable of performing most routine and specialty tests. Contact your Stago Representative for the most current listing. STA Compact Max® 4 Product Catalog 2015 Instruments (continued) Section 1 CAT. NO. PRODUCT/ DESCRIPTION 58104 STA Satellite® Hemostasis System Fully Automated, Low-Throughput Hemostasis Analyzer The STA Satellite® is a fully automated benchtop hemostasis analyzer capable of performing clotting, chromogenic and immunological assays simultaneously in random access mode. The system enables lntegrated Health Networks to standardize patient testing results including D-dimer and Anti-Xa. The STA Satellite® offers technological advances to ensure a high level of %"%>?&@"%+ Analyzer is provided with: • Accessory Kit • Operator’s reference manual • 1-year warranty Dimensions • Height . 27.4 inches • Width . 21.1 inches • Depth . 25.5 inches • Weight . 72 pounds Test Selections /!" Samples • 20 onboard sample capacity • Primary tube sampling • Removable sample carousel • Continous sample loading • =$ LIS Interface Bi-directional host-query Other Features • LED for colorimetric assays • Internal barcode reader for samples and reagents • Stago’s exclusive method of VDSTM Mechanical Clot Detection (Viscosity-based Detection System) technology Reagent Menu • PT • APTT • Fibrinogen • AT • Liquid Anti-Xa (UFH and LMWH) • D-dimer STA Satellite® 5 Section 1 Instruments (continued) CAT. NO. PRODUCT/ DESCRIPTION 58230 STart® Hemostasis Analyzer Benchtop Hemostasis Analyzer for Batch Testing The STart® is a benchtop hemostasis analyzer featuring Stago’s exclusive method of VDS™ Mechanical Clot Detection (Viscosity-based Detection System). This method eliminates interference from lipemic, icteric or other optically dense samples or reagents. The analyzer offers programmable and pre-programmed assays with curve storage, 4 independently-timed incubation stations, electronically-linked multiple pipettor, 40-character liquid crystal display and an internal thermal printer. Its lightweight, compact size makes it ideal for low to medium volume batch testing or as a back-up to an optical clot detection system. Analyzer is provided with: • Accessory kit • Cabled pipette • Operator’s reference manual • 1-year warranty Dimensions • Height . 4.7 inches • Width . 16.1 inches • Depth . 16.5 inches • Weight . 12.5 pounds Methodology Clotting - Standard VDS® Mechanical Clot Detection Test Selections • 17 test selections • Preprogrammed and programmable options Other Features • Electronically-linked multiple pipettor for convenience and accuracy • Integrated printer • Four independently-timed incubation stations with audible signal • Lightweight and compact Reagent Menu • PT • APTT • Fibrinogen • Thrombin Time • Reptilase Time • Extrinsic Factors • Intrinsic Factors • Protein C Activity • Protein S Activity • PTT-LA • Staclot® LA (Lupus Anticoagulants) • DRVV STart® 6 Product Catalog 2015 Disposables & Accessories Section 2 CAT. NO. PRODUCT/ DESCRIPTION CONTENTS STA-R Evolution®,
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002
    USOO6395889B1 (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002 (54) NUCLEIC ACID MOLECULES ENCODING WO WO-98/56804 A1 * 12/1998 ........... CO7H/21/02 HUMAN PROTEASE HOMOLOGS WO WO-99/0785.0 A1 * 2/1999 ... C12N/15/12 WO WO-99/37660 A1 * 7/1999 ........... CO7H/21/04 (75) Inventor: fish E. Robison, Wilmington, MA OTHER PUBLICATIONS Vazquez, F., et al., 1999, “METH-1, a human ortholog of (73) Assignee: Millennium Pharmaceuticals, Inc., ADAMTS-1, and METH-2 are members of a new family of Cambridge, MA (US) proteins with angio-inhibitory activity', The Journal of c: - 0 Biological Chemistry, vol. 274, No. 33, pp. 23349–23357.* (*) Notice: Subject to any disclaimer, the term of this Descriptors of Protease Classes in Prosite and Pfam Data patent is extended or adjusted under 35 bases. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/392, 184 Primary Examiner Ponnathapu Achutamurthy (22) Filed: Sep. 9, 1999 ASSistant Examiner William W. Moore (51) Int. Cl." C12N 15/57; C12N 15/12; (74) Attorney, Agent, or Firm-Alston & Bird LLP C12N 9/64; C12N 15/79 (57) ABSTRACT (52) U.S. Cl. .................... 536/23.2; 536/23.5; 435/69.1; 435/252.3; 435/320.1 The invention relates to polynucleotides encoding newly (58) Field of Search ............................... 536,232,235. identified protease homologs. The invention also relates to 435/6, 226, 69.1, 252.3 the proteases. The invention further relates to methods using s s s/ - - -us the protease polypeptides and polynucleotides as a target for (56) References Cited diagnosis and treatment in protease-mediated disorders.
    [Show full text]
  • Cross-Linking of Alpha 2-Plasmin Inhibitor to Fibrin by Fibrin- Stabilizing Factor
    Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin- stabilizing factor. Y Sakata, N Aoki J Clin Invest. 1980;65(2):290-297. https://doi.org/10.1172/JCI109671. Research Article The concentration of alpha 2-plasmin inhibitor in blood plasma is higher than that in serum obtained from the blood clotted in the presence of calcium ions, but is the same as that in serum obtained in the absence of calcium ions. Radiolabeled alpha2-plasmin inhibitor was covalently bound to fibrin only when calcium ions were present at the time of clotting of plasma or fibrinogen. Whereas, when batroxobin, a snake venom enzyme that lacks the ability to activate fibrin- stabilizing factor, was used for clotting fibrinogen, the binding was not observed. When fibrin-stablizing, factor-deficient plasma was clotted, the specific binding of alpha 2-plasmin inhibitor to fibrin did not occur even in the presence of calcium ions and the concentration of alpha 2-plasmin inhibitor in serum was the same as that in plasma. Monodansyl cadaverine, a fluorescent substrate of the fibrin-stablizing factor, was incorporated into alpha 2-plasmin inhibitor by activated fibrin-stablizing factor. All these findings indicate that alpha 2-plasmin inhibitor is cross-linked to fibrin by activated fibrin-stabilizing factor when blood is clotted. Analysis of alpha 2-plasmin inhibitor-incorporated fibrin by sodium dodecyl sulfate gel electrophoresis showed that the inhibitor was mainly cross-linked to polymerized alpha-chains of cross-linked fibrin. Cross-linking of alpha 2-plasmin inhibitor to fibrin renders fibrin clot less susceptible to fibrinolysis by plasmin.
    [Show full text]
  • Molecular Basis of Fibrinogen Naples Associated with Defective Thrombin Binding and Thrombophilia
    Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala----Thr. J Koopman, … , J Grimbergen, P M Mannucci J Clin Invest. 1992;90(1):238-244. https://doi.org/10.1172/JCI115841. Research Article In an abnormal fibrinogen (fibrinogen Naples) associated with congenital thrombophilia we have identified a single base substitution (G----A) in the B beta chain gene that results in an amino acid substitution of alanine by threonine at position 68 in the B beta chain of fibrinogen. The propositus and two siblings were found to be homozygous for the mutation, whereas the parents and another sibling were found to be heterozygous. Individuals homozygous for the defect had a severe history of both arterial and venous thrombosis; heterozygous individuals had no clinical symptoms. The three homozygotes had a prolonged thrombin clotting time in plasma, whereas the heterozygotes had a normal thrombin clotting time. Fibrinopeptide A and B (FpA and FpB) release from purified fibrinogen by human alpha-thrombin was delayed in both the homozygous propositus and a heterozygous family member. Release of FpA from the normal and abnormal amino-terminal disulfide knot (NDSK) corresponded to that found with the intact fibrinogens, indicating a decreased interaction of thrombin with the NDSK part of fibrinogen Naples. Binding studies showed that fibrin from homozygous abnormal fibrinogen bound less than 10% of active site inhibited alpha-thrombin as compared with normal fibrin, while fibrin formed from heterozygous abnormal fibrinogen bound approximately 50% of alpha-thrombin. These results suggest that the mutation of B beta Ala 68----Thr affects the binding of alpha-thrombin […] Find the latest version: https://jci.me/115841/pdf Molecular Basis of Fibrinogen Naples Associated with Defective Thrombin Binding and Thrombophilia Homozygous Substitution of BB 68 Ala -- Thr Jaap Koopman,** Frits Haverkate,t Susan T.
    [Show full text]
  • MGH Clinical Laboratories
    MGH Laboratory Handbook Online Lab Handbook: http://mghlabtest.partners.org Reference Intervals - MGH Clinical Laboratories MGH Department of Pathology 55 Fruit Street, GRJ 220 Boston, MA 02114-2696 Report generated: August 19, 2009 Test name Reference Interval Laboratory 1-25-OH Vitamin D Core lab (Sendouts) 1-3-Beta D glucan assay Core lab (Sendouts) 17-OH Progesterone Core lab (Sendouts) 25-OH Vitamin D Desired: > 32 ng/mL Core 3-Methylhistidine, urine Age matched reference range and interpretation Neurochemistry provided 5-Nucleotidase Core lab (Sendouts) A1AT deficiency profile Core lab (Sendouts) ABO/Rh Type Blood Transfusion Service Acetaminophen Negative Core Acetone Negative Core Acetylaspartate, urine Interpretation provided Neurochemistry ACTH 6-76 pg/ml Core Acylcarnitines (plasma) Core lab (Sendouts) ADAMTS13 activity/inhibitor Core lab (Sendouts) Adenosine deaminase (fluid--NOT CSF) Core lab (Sendouts) Adenovirus antibody Reported with results Microbiology Adenovirus antigen Negative Microbiology Adenylosuccinase deficiency, screen Interpretation provided Neurochemistry AFP (non-maternal specimens) Core Alanine, CSF Interpretation and age-matched reference ranges Neurochemistry provided. Wednesday, August 19, 2009 Page 1 of 26 Test name Reference Interval Laboratory Alanine, plasma Interpretation and age-matched reference ranges Neurochemistry provided. Albumin 3.1-4.3 g/dl Chelsea Healthcenter Albumin 3.3-5.0 g/dl Core Albumin (fluid--NOT CSF) Core Alcohols (ethanol, MeOH, isoprop) Negative Core Aldolase Core lab (Sendouts)
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Correlation of the Production of Plasminogen Activator with Tumor Metastasis in Bi 6 Mouse Melanoma Cell Lines
    [CANCER RESEARCH 40, 288-292, February 1980 0008-5472/80/0040-0000$02.00 Correlation of the Production of Plasminogen Activator with Tumor Metastasis in Bi 6 Mouse Melanoma Cell Lines Bosco Shang Wang,2 Gerard A. McLoughlin,3 Jerome P. Richie, and John A. Mannick Deportment of Surgery, Peter Bent Brigham Hospital (B. S. W., G. A. M., J. P. R., J. A. M.j, and Department of Pathology (B. S. W.j, Harvard Medical School, Boston, Massachusetts 02115 ABSTRACT circulating cancer cells were easily detected in patients whose blood had a higher level of FA. The correlation between the production of plasminogen ac Although the FA of a tumor has been suggested as correlat tivator (PA) of tumors and their metastatic potential was stud ing with its metastatic potential, direct and quantitative evi ied. Bi 6 melanoma cells and ‘‘Bi6 mets' ‘cells (harvested from dence to support this hypothesis is lacking. Therefore, we have the pulmonary metastatic nodules of C57BL/6J mice bearing investigated this issue by comparing the FA of the Bi 6 mouse Bi 6 isografts) were examined with respect to their fibrinolytic melanoma and several of its sublines varying in their potential activity (FA) in tissue culture. Bi 6 mets cells had a significantly for forming metastases. higher FA than did Bi 6 cells. Fl (a Bi 6 subline with a lower incidence of metastasis) and Fl 0 (a highly metastatic Bi 6 subline) were also studied. Fl 0 cells produced more FA than MATERIALS AND METHODS did Fi cells. The difference between the FA's of these tumors Tumors.
    [Show full text]
  • The Role of the Laboratory in Treatment with New Oral Anticoagulants
    Journal of Thrombosis and Haemostasis, 11 (Suppl. 1): 122–128 DOI: 10.1111/jth.12227 INVITED REVIEW The role of the laboratory in treatment with new oral anticoagulants T. BAGLIN Department of Haematology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK To cite this article: Baglin T. The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost 2013; 11 (Suppl. 1): 122–8. tion of thromboembolism in patients with atrial fibrilla- Summary. Orally active small molecules that selectively tion. For some patients, these drugs offer substantial and specifically inhibit coagulation serine proteases have benefits over oral vitamin K antagonists (VKAs). For the been developed for clinical use. Dabigatran etexilate, majority of patients, these drugs are prescribed at fixed rivaroxaban and apixaban are given at fixed doses and doses without the need for monitoring or dose adjustment. do not require monitoring. In most circumstances, these There are no food interactions and very limited drug inter- drugs have predictable bioavailability, pharmacokinetic actions. The rapid onset of anticoagulation and short half- effects, and pharmacodynamic effects. However, there life make the initiation and interruption of anticoagulant will be clinical circumstances when assessment of the therapy considerably easier than with VKAs. As with all anticoagulant effect of these drugs will be required. The anticoagulants produced so far, there is a correlation effect of these drugs on laboratory tests has been deter- between intensity of anticoagulation and bleeding. Conse- mined in vitro by spiking normal samples with a known quently, the need to consider the balance of benefit and risk concentration of active compound, or ex vivo by using in each individual patient is no less important than with plasma samples from volunteers and patients.
    [Show full text]
  • Approach to Coagulopathy in the Icu Dic and Thrombotic Emergencies
    APPROACH TO COAGULOPATHY IN THE ICU DIC AND THROMBOTIC EMERGENCIES NEIL KUMAR, MD UNIVERSITY OF ROCHESTER MEDICAL CENTER Disclosures u I have no financial disclosures u I am NOT A HEMATOLOGIST Outline u Review of hemostasis and coagulopathy u Discuss laboratory markers for coagulopathy u Discuss an approach to a few specific coagulopathies and thrombotic emergencies Outline u Review of hemostasis and coagulopathy u Discuss laboratory markers for coagulopathy u Discuss an approach to a few specific coagulopathies and thrombotic emergencies Coagulation u Coagulation is the process in which blood clots u Fibrinolysis is the process in which clot dissolves u Hemostasis is the stopping of bleeding or hemorrhage. u Ideally, hemostasis is a balance between coagulation and fibrinolysis Coagulation (classic pathways) Michael G. Crooks Simon P. Hart Eur Respir Rev 2015;24:392-399 Coagulation (another view) Gando, S. et al. (2016) Disseminated intravascular coagulation Nat. Rev. Dis. Primers doi:10.1038/nrdp.2016.37 Coagulation (yet another view) u Inflammation and coagulation intersect with platelets in the middle u An example of this is Disseminated Intravascular Coagulation. Gando, S. et al. (2016) Disseminated intravascular coagulation Nat. Rev. Dis. Primers doi:10.1038/nrdp.2016.37 Outline u Review of hemostasis and coagulopathy u Discuss laboratory markers for coagulopathy u Discuss an approach to a few specific coagulopathies and thrombotic emergencies PT / INR u Prothrombin Time u Test of Extrinsic Pathway u Take plasma (blood without cells) and re-add calcium u Calcium was removed with citrate in tube u Add tissue factor u See how long it takes to clot and normalize PT to get INR Coagulation (classic pathways) Michael G.
    [Show full text]
  • Diagnosis of Hemophilia and Other Bleeding Disorders
    Diagnosis of Hemophilia and Other Bleeding Disorders A LABORATORY MANUAL Second Edition Steve Kitchen Angus McCraw Marión Echenagucia Published by the World Federation of Hemophilia (WFH) © World Federation of Hemophilia, 2010 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. For permission to reproduce or translate this document, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s website at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel.: (514) 875-7944 Fax: (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org Diagnosis of Hemophilia and Other Bleeding Disorders A LABORATORY MANUAL Second Edition (2010) Steve Kitchen Angus McCraw Marión Echenagucia WFH Laboratory WFH Laboratory (co-author, Automation) Training Specialist Training Specialist Banco Municipal Sheffield Haemophilia Katharine Dormandy de Sangre del D.C. and Thrombosis Centre Haemophilia Centre Universidad Central Royal Hallamshire and Thrombosis Unit de Venezuela Hospital The Royal Free Hospital Caracas, Venezuela Sheffield, U.K. London, U.K. on behalf of The WFH Laboratory Sciences Committee Chair (2010): Steve Kitchen, Sheffield, U.K. Deputy Chair: Sukesh Nair, Vellore, India This edition was reviewed by the following, who at the time of writing were members of the World Federation of Hemophilia Laboratory Sciences Committee: Mansoor Ahmed Clarence Lam Norma de Bosch Sukesh Nair Ampaiwan Chuansumrit Alison Street Marión Echenagucia Alok Srivastava Andreas Hillarp Some sections were also reviewed by members of the World Federation of Hemophilia von Willebrand Disease and Rare Bleeding Disorders Committee.
    [Show full text]
  • Tracking Oxidation-Induced Alterations in Fibrin Clot Formation by NMR
    www.nature.com/scientificreports OPEN Tracking oxidation‑induced alterations in fbrin clot formation by NMR‑based methods Wai‑Hoe Lau1, Nathan J. White2, Tsin‑Wen Yeo1,4, Russell L. Gruen3* & Konstantin Pervushin5* Plasma fbrinogen is an important coagulation factor and susceptible to post‑translational modifcation by oxidants. We have reported impairment of fbrin polymerization after exposure to hypochlorous acid (HOCl) and increased methionine oxidation of fbrinogen in severely injured trauma patients. Molecular dynamics suggests that methionine oxidation poses a mechanistic link between oxidative stress and coagulation through protofbril lateral aggregation by disruption of AαC domain structures. However, experimental evidence explaining how HOCl oxidation impairs fbrinogen structure and function has not been demonstrated. We utilized polymerization studies and two dimensional‑nuclear magnetic resonance spectrometry (2D‑NMR) to investigate the hypothesis that HOCl oxidation alters fbrinogen conformation and T2 relaxation time of water protons in the fbrin gels. We have demonstrated that both HOCl oxidation of purifed fbrinogen and addition of HOCl‑ oxidized fbrinogen to plasma fbrinogen solution disrupted lateral aggregation of protofbrils similarly to competitive inhibition of fbrin polymerization using a recombinant AαC fragment (AαC 419–502). DOSY NMR measurement of fbrinogen protons demonstrated that the difusion coefcient of fbrinogen increased by 17.4%, suggesting the oxidized fbrinogen was more compact and fast motion in the prefbrillar state. 2D‑NMR analysis refected that water protons existed as bulk water (T2) and intermediate water (T2i) in the control plasma fbrin. Bulk water T2 relaxation time was increased twofold and correlated positively with the level of HOCl oxidation. However, T2 relaxation of the oxidized plasma fbrin gels was dominated by intermediate water.
    [Show full text]
  • Effect of Intravenous Thrombolysis with Alteplase on Clinical Efficacy
    Brazilian Journal of Medical and Biological Research (2021) 54(5): e10000, http://dx.doi.org/10.1590/1414-431X202010000 ISSN 1414-431X Research Article 1/8 Effect of intravenous thrombolysis with alteplase on clinical efficacy, inflammatory factors, and neurological function in patients with acute cerebral infarction Jinhua Wang1 00 00, Xia Fang2 00 , Dongliang Wang1 00 , and Yuan Xiao1 00 1Department of Neurology, The People’s Hospital of Beilun District, Beilun Branch Hospital of The First Affiliated Hospital, Zhejiang University School of Medicine, Ningbo, Zhejiang Province, China 2Department of Gynecology, The People’s Hospital of Beilun District, Beilun Branch Hospital of The First Affiliated Hospital, Zhejiang University School of Medicine, Ningbo, Zhejiang Province, China Abstract This study aimed to explore the effect of intravenous thrombolysis with alteplase on clinical efficacy, inflammatory factors, and neurological function in patients with acute cerebral infarction. A total of 120 patients with acute cerebral infarction were divided into two groups by the random number table method, with 60 patients in each group: observation group (intravenous thrombolysis with alteplase) and control group (intravenous thrombolysis with batroxobin). The clinical efficacy after a 14-day treatment was observed. Serum C-reactive protein (CRP), tumor necrosis factor a (TNF-a), interleukin-6 (IL-6), CD62p, GMP- 140, and neuron-specific enolase (NSE) were measured. Scores of National Institutes of Health Stroke Scale (NIHSS), Mini- Mental State Examination (MMSE), and Montreal Cognitive Assessment (MoCA) were determined. The total effective rate in the observation group was 81.67%, which was higher than the 61.67% in the control group (Po0.05).
    [Show full text]
  • Distinctive Role of Histidine-16 of the B,8 Chain of Fibrinogen in the End-To
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 591-593, February 1986 Biochemistry Distinctive role of histidine-16 of the B,8 chain of fibrinogen in the end-to-end association of fibrin (polymerization/chemical modification/affinity chromatography) AKIRA SHIMIZU, YUJI SAITO, AND YUJI INADA Laboratory of Biological Chemistry, Tokyo Institute of Technology, Ookayama, Meguro-ku, Tokyo 152, Japan Communicated by John D. Ferry, September 12, 1985 ABSTRACT Photooxidation of fibrinogen reduced the includes 17th to 19th amino acid residues in Aa chain of batroxobin-induced fibrin polymerization. The fibrin fragment fibrinogen, specifically inhibits fibrin association and has des-AB N-DSK, which contains the binding sites termed A and proved itselfuseful for the elucidation ofassociation sites (7). B, lost the ability to bind to the site termed a in fibrinogen- These examples stress the critical role played by arginine-19 Sepharose upon the oxidation of histidine-16 in the BP chain of of Aa chain and some residues adjacent to it in the NH2- fibrinogen [Shimizu, A., Saito, Y., Matsushima, A. & Inada, terminal domain. On the other hand, very short fragments Y. (1983) J. Biol. Chem. 258, 7915-7917]. Some of the derived from the y chain of the COOH-terminal domain fragments, which became unable to bind to fibrinogen-Seph- (threonine-374 to valine-411 or threonine-374 to glutamic arose due to the destruction of site A, however, retained the acid-396) quite efficiently inhibited the association and sug- ability to bind to D-dimer-Sepharose, which contains both sites gested the importance ofthat region for the association (8, 9).
    [Show full text]